BackXilio Therapeutics Overview

Xilio Therapeutics Receivables

Latest receivables for XLO: $6M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$6.00M

Peer trimmed avg / median

Loading

Xilio Therapeutics Receivables History

Loading

Xilio Therapeutics vs. peers: Receivables Comparison

Loading

Xilio Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Xilio Therapeutics (XLO) FAQ

Xilio Therapeutics (XLO) currently reports a receivables of $6M as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Xilio Therapeutics's receivables history and peer comparisons.

Xilio Therapeutics's receivables changed from $0 to $6M (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Xilio Therapeutics reported $6M in receivables as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Xilio Therapeutics, and consider following XLO for alerts when major investors trade the stock.

Xilio Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XLO with unrelated industries.